NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, has agreed to acquire a 2016-built 180,000 dwt high-specification Capesize vessel for a purchase price of $47.5 million. Genco expects to take delivery of the vessel, to be named the Genco Intrepid, within the next 30 days, and intends to fund the acquisition with cash on hand and a drawdown from its revolving credit facility. John C. Wobensmith, Chief Executive Officer, commented, “We are pleased to continue to advance our growth strategy with the acquisition of this modern, fuel-efficient Capesize vessel. The purchase is consistent with our stated objective of reinvesting proceeds from the sale of older, less...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ECKOH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, is pleased to announce the acquisition of IntiQuan AG, a premier Swiss boutique specializing in pharmacometric services for the biopharmaceutical sector. Founded in Switzerland in 2015 by Dr. Henning Schmidt, IntiQuan has rapidly established itself as a trusted provider of cutting-edge pharmacometric and statistical modelling & simulation services. The acquisition expands PLG’s portfolio of specialized solutions that support biopharmaceutical companies with drug development, adding a key set of capabilities focused on significantly reducing development risk, costs and timelines and enhancing patient safety through advanced dose-response...

PRESS RELEASE Paris – October 07, 2024 Bureau Veritas refocuses its portfolio in line with its LEAP | 28 strategy and enters into an agreement to sell its Food testing business to Mérieux NutriSciences. Bureau Veritas, a global leader in Testing, Inspection, and Certification services, announced today that it has entered into an agreement to sell its Food testing business (EUR 133 million in revenue in 2023) to Mérieux NutriSciences for an Enterprise Value of EUR 360 million and net proceeds from disposals of around EUR290 million. This divestment reflects the Group’s active portfolio management, in line with Bureau Veritas’ LEAP | 28 strategy. The Group aims to focus its portfolio on served markets where it targets top leadership and performance positions by 2028. The food testing business is a laboratory activity serving customers in...

PRESS RELEASE Paris – October 07,2024 Bureau Veritas enhances its Buildings & Infrastructure solutions through Buildings & Information Modeling digital enablement by acquiring IDP Group IDP Group to become a new Bureau Veritas Global Technical Center for BIM and Digital Solutions for Buildings & Infrastructure and Energy Bureau Veritas, a global leader in Testing, Inspection, and Certification services, today announced the acquisition of IDP Group, a leading independent provider of BIM (Building Information Modeling), Project Management Assistance and Digital Twin services for the public and private sector, with strong positioning in decarbonization and other high-value verticals. This acquisition is aligned with Bureau Veritas LEAP | 28 strategy to expand leadership in B&I, while investing in strategic and promising...

To assist more corporates to meet net zero carbon ambitions and reduce energy consumption LONDON, Oct. 06, 2024 (GLOBE NEWSWIRE) — Projective is pleased to announce that Bonheur ASA, the Norway-based industrial investment company listed on the Oslo Stock Exchange, has acquired a controlling stake in the Company. Building on 176 years of experience in renewable energy, shipping, and various maritime activities, Bonheur has developed a strong ecosystem of renewable energy-related companies. Projective is a global technical consulting and engineering firm specialising in providing tailored solutions to large blue chip companies across various industries, including pharmaceuticals, food and beverage, FMCG, brewing and distilling, utilities, manufacturing, chemical processing, commercial and public real estate, and energy. Established...

— OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer — On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 — Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 — Shares to trade on Nasdaq under the new ticker symbol “OKUR” commencing on October 7, 2024 BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) — OnKure Therapeutics, Inc. (Nasdaq: OKUR) (“OnKure”), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced the completion of its previously announced merger of OnKure,...

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, 2024, Psyence Biomed has decided not to proceed with the acquisition at this time. Psyence Biomed continues to advance its recently initiated Phase IIb clinical trial of nature derived psilocybin in conjunction with psychotherapy as a potential treatment for Adjustment Disorder following a life-limiting cancer diagnosis in Palliative Care. The first patient is expected to...

Innofactor Plc              Stock Exchange Release              October 4, 2024 at 6:35 p.m. (EEST) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, PLEASE SEE SECTION ENTITLED “IMPORTANT INFORMATION” BELOW. Preliminary result of the subsequent offer period of Onni Bidco Oy’s voluntary recommended public cash tender offer for all the shares in Innofactor Plc As announced on July 22, 2024, CapMan Growth Equity Fund III Ky, a fund managed by CapMan Group affiliated companies, (“CapMan Growth”), Sami Ensio, the founder, CEO and member of the Board of Directors of Innofactor Plc, through the holding company...